Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycerin + hypromellose + polyethylene glycol (Wills Eye Hospital)
- Development stage
- Unknown
- Lead developer
- Wills Eye Hospital
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
This combination ophthalmic solution contains glycerin (0.2%), hypromellose (0.2%), and polyethylene glycol (1.0%), which function as lubricants and demulcents to protect and hydrate the ocular surface. In the clinical trial context provided by Wills Eye Hospital (NCT05514301), this formulation is utilized as a pharmacologically inactive placebo control to evaluate the safety and efficacy of netarsudil 0.02% ophthalmic solution in preventing proliferative vitreoretinopathy (PVR) in patients undergoing repair for rhegmatogenous retinal detachment (RRD). The ingredients work by stabilizing the tear film and providing a protective barrier over the corneal epithelium, thereby reducing irritation and dryness without exerting specific anti-fibrotic or rho-kinase inhibitory effects.
- Other names
- Artificial tearsGlycerin 0.2% / Hypromellose 0.2% / Polyethylene glycol 1% ophthalmic solution
Beyond the preview
Go deeper on glycerin + hypromellose + polyethylene glycol (Wills Eye Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycerin + hypromellose + polyethylene glycol (Wills Eye Hospital).